Title
Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses
A Randomized, Parallel-Group, Vehicle-Controlled, Double-Blind Study of Topical Imiquimod 5% Cream Used as an Adjunct to Cryotherapy in the Management of Actinic Keratoses, With a Long-Term (1 Year) Follow-Up
Phase
Phase 4Lead Sponsor
Derm Research @ 888 Inc.Study Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Keratosis Actinic KeratosisIntervention/Treatment
imiquimod ...Study Participants
60Study Aims:
To compare the long-term efficacy and safety of imiquimod versus vehicle used as an adjunct to cryotherapy.
To assess and compare the recurrence rate and time to recurrence of the 2 different treatment groups.
Hypothesis: The imiquimod arm will produce a more prolonged clearing of Actinic Keratoses (AK) compared to the vehicle arm.
Evaluation of: (i) topical imiquimod 5% cream or (ii) vehicle cream used two times weekly for eight weeks starting two weeks post cryotherapy.
Study Aims:
To assess and compare the recurrence rate and time to recurrence of the 2 different treatment groups.
To assess and compare the efficacy of the 2 different treatment groups.
To assess and compare the safety of the 2 different treatment groups.
Study Design: 6 visits over 62 weeks
Inclusion Criteria: Diagnosis of actinic keratosis with 4 or more discreet lesions on the face or balding scalp. Lesions must be within a treatment area not exceeding 50 cm2 (combined total must not exceed 50 cm2) Women of childbearing potential using appropriate contraceptive methods Exclusion Criteria: Previous treatments with imiquimod for AK in the prescribed area within the past 5 months or cryosurgery in the same area within the past 4 weeks. Patients unwilling to stay out of the sun or wear protective clothing or to use sunscreen with a minimum of SPF 15 during the study. Basal or squamous cell carcinomas in the prescribed treatment area in the past 2 years.